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Abstract
We aimed to compare fatigue of newly diagnosed patients with myelodysplastic syndromes (MDS) with that of the general
population (GP). We also investigated the ability of the IPSS and IPSS-R to capture severity of patient-reported fatigue at
diagnostic workup. A sample of 927 newly diagnosed patients with MDS was consecutively enrolled in a large international
observational study and all patients completed the FACIT-Fatigue questionnaire at baseline. Fatigue was compared with that
of the GP (N= 1075) and a 3-point difference in mean scores was considered as clinically meaningful. Fatigue of MDS
patients was on average 4.6 points below the mean of the GP (95% CI, −5.9 to −3.2, p < 0.001), reflecting clinically
meaningful worse fatigue. Unlike the IPSS, the IPSS-R identified clearly distinct subgroups with regard to burden of fatigue.
Mean scores differences compared with GP ranged from nonclinically relevant for very low risk (Δ=−1.8, 95% CI, −4.0 to
0.5, p= 0.119) to large clinically meaningful differences for very high-risk IPSS-R patients (Δ=−8.2, 95% CI, −10.3 to
−6.2, p < 0.001). At diagnostic workup, fatigue of MDS is clinically meaningful worse than that reported by the GP.
Compared with the IPSS classification, the IPSS-R provides a better stratification of patients with regard to fatigue severity.
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Myelodysplastic syndromes (MDS) are a group of clonal
diseases characterized by ineffective hematopoiesis, mole-
cular and cytogenic abnormalities, bone marrow failure, and
risk for progression to acute myeloid leukemia (AML)
[1, 2]. As anemia is a common peripheral blood abnormality
at clinical presentation [3], some patients might also be
transfusion-dependent already at the time of diagnosis,
which is a known indicator of greater disease severity and
poor prognosis [4].
As the disease course of MDS is highly variable in terms
of progression to AML and survival outcomes, major efforts
have been made over the years to develop prognostic
indices to help inform clinical decision-making [5]. The two
most frequently used disease-risk classifications in the MDS
diagnostic workup are the International Prognostic Scoring
System (IPSS) [6] and the IPSS-Revised (IPSS-R) [7].
While the IPSS-R was more recently developed, the IPSS is
still a very often used index in clinical practice to guide
individual treatment decisions [8].
Two decades ago, the international working group
standard response criteria for evaluation of MDS therapies
recommended that health-related quality of life (HRQOL)
be included in clinical research [9]. However, only recently
have there been major international efforts to develop dis-
ease specific HRQOL measures [10] or to conduct large-
scale HRQOL studies of MDS [11, 12]. Critical to the
global HRQOL of patients with MDS, more than degree of
anemia, is fatigue [13]. Fatigue is a hallmark of MDS
reported by the vast majority of patients [14], it is associated
with substantial level of distress [15] and, at least in high-
risk patients, it was shown to provide independent prog-
nostic information for survival beyond well-established
prognostic indices [16].
However, very little data are available on patient-
reported fatigue in MDS. For example, it is not known if
the level of fatigue experienced by newly diagnosed
patients with MDS is different from that reported by the
general population (GP) and whether standard disease-risk
classifications used in the diagnostic workup capture this
key symptom. This data could be critical to understanding
the initial burden of fatigue in this population, before pos-
sible changes due to commonly used therapies for MDS,
such as erythropoiesis-stimulating agents or hypomethylat-
ing agents [17, 18]. Such information could also lay the
groundwork for developing more timely and personalized
treatment approaches and enhancing patients’ management
in clinical practice.
Our primary objective was to compare self-reported
fatigue between patients with newly diagnosed MDS and
the GP. Secondary objectives were to examine burden of
fatigue by transfusion dependency status and by risk-group
categories defined by the routinely used IPSS and IPSS-R
risk classifications.
Methods
Between November 2008 and December 2018, 927 newly
diagnosed patients with MDS were consecutively enrolled
in an international prospective cohort observational study
involving 53 centers across eleven countries (Austria, Bel-
gium, Brazil, China, Croatia, Czech Republic, France,
Germany, Italy, UK, USA). The primary objective of this
study was to investigate the prognostic value of baseline
patients’ reported fatigue for overall survival and follow-up
of patients is ongoing. Patients were diagnosed and classi-
fied according to the World Health Organization criteria
[19, 20]. The initial protocol only included patients with
MDS with higher risk disease (i.e., IPSS intermediate-2 or
high-risk classifications) but was later amended in Sep-
tember 2014 to also include patients diagnosed with lower
risk disease (i.e., IPSS low and intermediate-1 risk classi-
fications) within 3 months of the date of registration.
Baseline assessment of patient-reported HRQOL was
mandatory for inclusion in this study and the EORTC QLQ-
C30 [21] and the FACIT-Fatigue [22] questionnaires were
administered to patients at study entry. Exclusion criteria
included having received any kind of therapy (other than
transfusions) and having any kind of psychiatric disorder or
major cognitive dysfunction.
The study was approved by all Ethic Committees of each
participating center, and all patients provided informed
consent according to local national regulations. The study
was conducted in accordance with the Declaration of Hel-
sinki and registered at ClinicalTrials.gov (NCT00809575).
General population (GP)
For these analyses, data from patients with MDS were
compared with data from a GP sample for whom self-
reported fatigue was assessed using the same well-validated
FACIT-Fatigue questionnaire [22]. Data for the GP refer-
ence group were collected by Knowledge Networks (KN;
Menlo Park, CA), a marketing information and decision
support system. KN drew a random sample of individuals at
least 18 years old in the United States from an internet-
based survey panel of more than 100,000 individuals who
were a demographically representative sample of the GP
and responded to one survey per month in exchange for free
installation of WebTV internet service. The FACIT-Fatigue
was one such survey that was presented electronically to the
panel members to complete in their homes. Of 1075 indi-
viduals who completed the FACIT-Fatigue, 61 were
excluded from these analyses because they reported a
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current or historic cancer diagnosis and an additional 203
were excluded because they were <30 years old (the mini-
mum age in the sample of patients with MDS). In total, 811
participants (47.6% male, mean age 50.1 years) were
retained from the GP; these participants are a largely
overlapping subset of individuals that have previously been
used as a GP reference group by which to compare the
fatigue levels of patients with MDS [14] and anemic cancer
patients [23].
Assessment of patient-reported fatigue in both
samples
The 13-item FACIT-Fatigue scale assesses self-reported
tiredness, weakness, and difficulty participating in usual
activities due to fatigue over the past seven days [22, 24]
(Fig. 1). Respondents indicate the veracity of statements
related to fatigue (e.g., “I feel weak all over,” “I have
trouble starting things because I am tired”) on a Likert scale
from not at all (0) to very much [4]. Per the scoring
guidelines, negatively worded items were reverse scored
and summed such that higher total values (range 0–52)
indicate better functioning; thus, lower values indicate more
fatigue [22]. For comparison purposes, a difference of at
least 3 points in the FACIT-Fatigue score is considered
clinically meaningful [22, 25]. For the purpose of this study,
only baseline fatigue scores of the MDS population were
used in order to ensure that comparison of their fatigue
scores with the GP were not confounded by factors such as
receipt of active MDS treatments.
Statistical analyses
We summarized the main characteristics of patients with
MDS and the GP by frequencies, proportions, means,
standard deviations, medians, and interquartile ranges as
appropriate. All patients were described based on widely
used broader risk categories, that is: “lower” and “higher”
risk patients [18]. For the IPSS risk classification, these
included, respectively, those patients classified as low and
intermediate-1 risk vs. those classified as intermediate-2
and high risk. For the IPSS-R risk classification, these
included, respectively, those patients classified as very low,
low, and intermediate (with an IPSS-R score ≤ 3.5), vs.
those classified as intermediate (with an IPSS-R score
>3.5), high, and very high [26].
We estimated the overall mean difference in FACIT-
Fatigue scores between patients with MDS and the GP,
adjusted by age, sex, and presence of at least one comor-
bidity [27] (yes vs. no) using a multivariable linear
regression (MLR) model also including a binary status
indicator (MDS vs. GP). We separately ran the same MLR
model to estimate adjusted mean differences in fatigue
between patients with MDS and the GP also by MDS-based
Fig. 1 The Functional
Assessment of Chronic Illness
Therapy (FACIT) Fatigue
Questionnaire. This is the
questionnaire that was used to
assess patient-reported fatigue in
the current study.
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subgroups. These were defined respectively by IPSS risk
categories (low, intermediate-1, intermediate-2, and high),
IPSS-R (very low, low, intermediate, high, and very high)
and transfusion dependency (yes vs. no). This latter was
defined a priori in the protocol as having received at least
one red blood cell transfusion every 8 weeks over a period
of 4 months [4]. We also performed supportive analysis,
estimating the mean differences in fatigue scores between
MDS and GP on an exact age–sex matched subsample. For
descriptive purposes, we also computed the cumulative
distribution of fatigue scores in patients with MDS and the
GP. In addition, we reported the proportions of patients
with MDS with a level of fatigue severity equal to or
worse than the mean and the median fatigue levels in the
GP, respectively, both by IPSS and IPSS-R risk
categories. All statistical tests were two-sided and statistical
significance was set as α= 0.05. All analyses were per-
formed by SAS software v.4 (SAS Institute Inc., Cary,
NC, USA).
Results
The overall sample of patients with MDS was comprised
of mostly males (n= 568/927, 61.3%) with a mean age of
71.6 years (SD= 10.7). Patients with MDS were further
classified into lower and higher risk disease according to
both the IPSS and IPSS-R risk classifications and
described by the following characteristics: age, sex, time
since diagnosis, ECOG performance status, peripheral
cytopenias (i.e., hemoglobin levels, platelets, and absolute
neutrophils count), presence of comorbidities, and
transfusion dependency. The top three most prevalent
MDS subtypes were RAEB-2 (n= 317, 34.2%), RCMD
(n= 208, 22.4%) and RAEB-1 (n= 175, 18.9%),
while the median percentage of blasts was 5.6% (inter-
quartile range from 2% to 12%). Overall, there were 153
(16.5%) patients who were transfusion-dependent at
baseline. Details of patient’s characteristics are reported in
Table 1.
Fatigue in patients with MDS compared with the GP
In the GP, the mean FACIT-Fatigue score was 40.6 (SD=
10, median 44) compared with patients with MDS who
reported a mean score of 36.3 (SD= 11.4, median 39).
FACIT-Fatigue scores among patients with MDS were on
average 4.6 points below the mean of the GP (95% CI, −5.9
to −3.2, p < 0.001), reflecting clinically meaningful worse
fatigue in patients with MDS (Table 2). The magnitude and
direction of the estimated mean difference in fatigue scores
between patients with MDS and GP were also confirmed in
supportive analysis (data not shown).
Figure 2 shows the cumulative distribution of FACIT-
Fatigue scores in patients with MDS and the GP. Overall,
59% (n= 542/923) and 71% (n= 659/923) of patients with
MDS reported fatigue levels equal to or worse than the
mean and the median fatigue level in the GP.
Table 1 Characteristics of patients with MDS by lower and higher risk





Lowerb Higherc Lowerd Highere
Sex; n (%)
Male 301 (59.5) 267 (63.4) 224 (58.8) 328 (63.0)
Female 205 (40.5) 154 (36.6) 157 (41.2) 193 (37.0)
Age, years
Median 74.5 72.0 74.0 72.9
Range (IQR) 68.0–80.0 64.0–78.0 66.6–79.3 66.0–78.8
Time since diagnosis (weeks)
Median 0.0 0.0 4.3 0.0
Range (IQR) 0.0–4.4 0.0–4.4 0.0–4.3 0.0–4.3
ECOG performance status; n (%)
0 229 (46.0) 136 (32.5) 193 (51.3) 167 (32.4)
1 220 (44.2) 199 (47.5) 157 (41.8) 247 (47.8)
≥2 49 (9.8) 84 (20.0) 26 (6.9) 102 (19.8)
Missing 8 (.) 2 (.) 5 (.) 5 (.)
Hemoglobin levels; g/dL
Median 9.9 9.1 10.3 9.0
Range (IQR) 8.8–11.6 8.2–10.4 9.1–12.0 8.1–10.2
Platelets count; 109/L
Median 127.5 71.0 139.0 73.0
Range (IQR) 70.0–239.0 37.0–120.0 84.0–249.0 39.0–132.0
Absolute neutrophil count; 109/L
Median 2.1 1.0 2.3 1.1
Range (IQR) 1.2–3.6 0.5–1.9 1.4–3.8 0.6–2.1
Presence of comorbiditiesf; n (%)
No 223 (44.3) 198 (47.1) 180 (47.4) 231 (44.5)
Yes (at least one) 281 (55.7) 222 (52.9) 200 (52.6) 288 (55.5)
Missing 2 (.) 1 (.) 1 (.) 2 (.)
Transfusion dependencyg; n (%)
No 437 (87.1) 330 (78.9) 338 (89.0) 415 (80.6)
Yes 65 (12.9) 88 (21.1) 42 (11.0) 100 (19.4)
Not available 4 (.) 3 (.) 1 (.) 6 (.)
IPSS International Prognostic Scoring System, IPSS-R International
Prognostic Scoring System-Revised, IQR interquartile range.
aN= 902, 25 patients with MDS were missing IPSS-R classification.
bIncluding patients with IPSS low and intermediate-1 risk.
cIncluding patients with IPSS intermediate-2 and high-risk.
dThe “lower” category includes patients classified according to the
IPSS-R index as “very low”, “low,” and those “intermediate” with an
IPSS-R score ≤3.5.
eThe “higher” category includes patients classified according to the
IPSS-R index as “high”, “very high,” and those “intermediate” with an
IPSS-R score >3.5.
fComorbidity has been measured using the hematopoietic cell
transplantation-comorbidity index (HCT-CI).
gTransfusion dependency was defined as having received at least one
red blood cell transfusion every 8 weeks over a period of 4 months.
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Fatigue in patients with MDS by transfusion
dependency compared with the GP
The mean FACIT-Fatigue scores were statistically and
clinically meaningfully worse than in the GP in both groups
of transfusion-independent (Δ=−3.7, 95% CI, −5.1
to −2.3, p < 0.001) and transfusion-dependent (Δ=−8.5,
95% CI, −10.6 to −6.4, p < 0.001) patients with MDS
(Table 2).
Figure 3 shows the cumulative distribution of FACIT-
Fatigue scores in patients with MDS by transfusion depen-
dency status and the GP. There were 56% (n= 425/764)
Table 2 Adjusted mean
differences in FACIT-Fatigue
scores between the GP and
patients with MDS, overall, by
transfusion dependency and by
IPSS and IPSS-R risk
classifications.
Mean SD Mean difference from GP
(95% CI)a
p Magnitude of clinical
significanceb
General population (GP) 40.6 10.0
MDS total samplec 36.3 11.4 −4.6 (−5.9, −3.2) <0.001 *
Transfusion dependencyd
No 37.1 11.1 −3.7 (−5.1, −2.3) <0.001 *
Yes 32.4 12.0 −8.5 (−10.6, −6.4) <0.001 **
MDS by IPSS risk
Low 38.3 11.2 −3.0 (−4.8, −1.1) 0.002 *
Intermediate-1 37.1 10.7 −3.3 (−5.0, −1.5) <0.001 *
Intermediate-2 35.2 11.7 −6.0 (−7.7, −4.3) <0.001 **
High 33.3 11.6 −8.1 (−10.3, −5.8) <0.001 **
MDS by IPSS-R risk
Very low 39.9 9.1 −1.8 (−4.0, 0.5) 0.119 NR
Low 37.7 11.7 −3.3 (−5.2, −1.5) <0.001 *
Intermediate 36.3 11.2 −4.1 (−6.0, −2.1) <0.001 *
High 35.3 10.7 −5.2 (−7.1, −3.3) <0.001 *
Very high 33.6 12.5 −8.2 (−10.3, −6.2) <0.001 **
CI confidence intervals, GP general population, MDS myelodysplastic syndromes, IPSS International
Prognostic Scoring System, IPSS-R International Prognostic Scoring System-Revised, NR not reached, SD
standard deviation.
aMean difference score adjusted for age, sex, and presence of comorbidity.
b*= reaching at least a 3-points difference, **= reaching at least a 6-points difference.
cFour patients with MDS were excluded due to not evaluable FACIT-Fatigue questionnaire; for the FACIT-
Fatigue measure, lower scores indicate worse fatigue levels.
dTransfusion dependency was defined as having received at least one red blood cell transfusion every
8 weeks over a period of 4 months.
Fig. 2 Cumulative distribution
of FACIT-Fatigue scores in
patients with MDS and the
general adult population.
Starting from the left side of the
figure, the height of each curve
represents the overall proportion
of individuals reporting an equal
or higher fatigue burden than
that represented by the
corresponding FACIT-fatigue
score. The vertical line
represents the mean FACIT-
Fatigue score in the general
population.
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and 73% (n= 112/153) of transfusion-independent and
transfusion-dependent patients, respectively, who reported
fatigue levels equal to or worse than the mean fatigue level in
the GP. In addition, 69% (n= 526) and 83% (n= 127) of
transfusion-independent and transfusion-dependent patients,
respectively, reported fatigue levels equal to or worse than the
median fatigue level in the GP.
Fatigue in patients with MDS compared with the GP
by IPSS risk categories
Adjusted mean score differences of patients with MDS
compared with the GP reached the clinically meaningful
threshold of 3 points in both lower risk groups; patients with
MDS with low risk reported FACIT-Fatigue scores an
average of 3 points lower than the GP (95% CI, −4.8 to
−1.1, p= 0.002) and patients with MDS with intermediate-
1 risk reported FACIT-Fatigue scores an average of 3.3
points lower than the GP (95% CI, −5.0 to −1.5, p <
0.001). With regard to higher risk patients with MDS, mean
score differences with the GP exceeded twice the 3-point
meaningful difference in both the intermediate-2 (Δ=−6,
95% CI, −7.7 to −4.3, p < 0.001) and the high (Δ=−8.1,
95% CI, −10.3 to −5.8, p < 0.001) risk groups (Table 2).
Fatigue in patients with MDS compared with the GP
by IPSS-R risk categories
The adjusted mean difference in FACIT-Fatigue scores
between patients with very low risk and the GP was neither
statistically nor clinically significant. In contrast, patients in
the all other risk categories showed both statistically sig-
nificant and clinically meaningful adjusted mean differences
in FACIT-Fatigue scores, indicating progressively worse
fatigue levels as IPSS-R risk category increased. These were
patients with low (Δ=−3.3, 95% CI, −5.2 to −1.5, p <
0.001), intermediate (Δ=−4.1, 95% CI, −6.0 to −2.1, p <
0.001), high (Δ=−5.2, 95% CI, −7.1 to −3.3, p < 0.001),
and very high-risk classifications (Δ=−8.2, 95%
CI, −10.3 to −6.2, p < 0.001) (Table 2). The difference in
fatigue reported by patients with very high risk vs. the GP
exceeded twice the clinically meaningful threshold.
For descriptive purposes, the trend found between
increased fatigue severity by IPSS-R risk-group categories
is graphically depicted in Fig. 4.
Discussion
We have shown that the burden of fatigue experienced by
newly diagnosed patients with MDS at the time of diag-
nostic workup is worse, both statistically and clinically, than
that reported by the GP. Notably, we observed that this
holds true not only for patients who were transfusion-
dependent at clinical presentation, but also for those who
were not, thereby showing the major negative impact of the
disease itself on patients’ lives. To the best of our knowl-
edge, this is the first study to also document fatigue severity
in MDS across the whole spectrum of baseline risk-group
categories, covering both lower and higher risk patients, as
defined by the most widely used disease-risk classifications
(i.e., IPSS and IPSS-R).
Fig. 3 Cumulative distribution of FACIT-Fatigue scores in
patients with MDS by transfusion dependency and the general
adult population. Transfusion dependency was defined as having
received at least one red blood cell transfusion every 8 weeks over a
period of 4 months. Starting from the left side of the figure, the height
of each curve represents the overall proportion of individuals reporting
an equal or higher fatigue burden than that represented by the corre-
sponding FACIT-fatigue score. The vertical line represents the mean
FACIT-Fatigue score in the general population.
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Steensma and colleagues [14] performed an internet-
based survey on 359 pretreated patients with MDS (mean
time since diagnosis was slightly more than 2 years), of
whom 66% had received treatments beyond transfusion
support therapies. They found that fatigue was associated
with significant impairment in broader HRQOL domains
and, similar to our findings, they noted that fatigue reported
by patients with MDS was greater than that reported by the
GP. However, it is difficult to make a direct comparison
with our results, as patients in the prior study had already
begun treatment whereas ours were treatment naïve.
Moreover, being an internet-based survey, data on disease-
risk classification were not available for more refined ana-
lyses in the prior study. Another internet-based survey
conducted with 145 patients with MDS also observed that
fatigue was a key concern in this population, even after
many years post diagnosis (mean time from diagnosis was
6.6 years). This study found that patient perceived energy
preservation, physical activity, and naps were the most
helpful strategies for managing fatigue [28].
Another finding from our study was the difference in the
ability of the IPSS and the IPSS-R indices to capture
baseline fatigue burden. This data have major clinical
implications for further improving risk-adapted strategies
for managing MDS. When investigating the magnitude of
difference in fatigue severity between patients MDS and the
GP by stratifying patients according to the IPSS, there was a
lack of sensitivity in capturing the burden of fatigue across
its four risk-group categories. For example, patients classi-
fied in the two lower risk disease groups (i.e., low and
intermediate-1) both reported clinically meaningful worse
fatigue than the GP.
Conversely, when using the IPSS-R, we found a rather
proportional rise of fatigue severity as IPSS-R risk-group
categories increased in severity. Indeed, patients with the
lowest risk (i.e., very low) did not report a level of fatigue
different from the GP, while those classified in the highest
risk-group category (i.e., very high) reported differences
that exceeded twice the magnitude of a clinically mean-
ingful difference in fatigue severity. A possible explanation
of the markedly different ability of these two prognostic
indices in reflecting fatigue severity is the more refined
classification of the variables that are used to compute the
IPSS-R compared with the IPSS. For example, the IPSS-R
distinguishes between five cytogenetic subgroups (com-
pared with the three of the IPSS), and has more detailed
threshold of blast percentages, for example, separating
marrow blasts <5% into 0–2% and >2–<5%. In addition, the
IPSS-R includes more clinically relevant cutoff points of
cytopenias, and it also considers the depth of cytopenias,
rather than just the number of them as it is for the IPSS
index [7].
While both scoring systems are widely used in routine
practice, it should be noted that all drugs approved for this
disease have been developed using the traditional IPSS
classification [17] and this is still a commonly used index in
clinical practice to decide the choice of therapy for indivi-
dual patients [8].
Our findings of the better performance of the IPSS-R
(compared to the IPSS) in capturing patient-reported fatigue
suggest its use in clinical practice may enhance patient
management. For example, one of the key challenges of
treatment decision-making is to determine when patients
with lower risk disease at presentation should start therapy
[29] and to identify lower risk patients who may benefit the
most from earlier treatments [30]. Notably, we found var-
iations within the mostly broad lower risk group of patients
by the IPSS-R (i.e., very low, low, and intermediate risk).
Specifically, we observed that while the very low-risk group
did not report clinically meaningful worse fatigue than that
of the GP, this was not the case for those with low or
intermediate risk. This suggests that for these latter two
groups, interventions aimed at improving fatigue can be of
particular value.
This study has limitations. Although we considered the
two most commonly used disease-risk classification in
MDS to examine their ability to capture fatigue severity, it
should be noted that other prognostic indices are also
available [5]. In addition, further analyses will be necessary
to elucidate the possible relationships between burden of
fatigue and other symptoms or broader HRQOL aspects.
Our study also has notable strengths. We used a well-
validated patient-reported measure of fatigue which allowed
us to determine not only the statistical significance of our
findings but, most importantly, the magnitude of the clinical
impact of fatigue impairment. Also, to the best of our
knowledge, this is the largest study ever conducted to
examine fatigue in this population. Finally, given the
observational nature of the study across several centers, we
included patients with MDS who are most likely to be seen
Fig. 4 Mean differences in FACIT-Fatigue scores between MDS
patients and the GP by IPSS-R risk classification. Mean differences
were adjusted for age, sex, and presence of comorbidity. Connecting
lines among adjusted mean differences of different MDS risk groups
were plotted only for descriptive purposes. The gray shaded area
indicates that the difference lies below the threshold for a clinically
meaningful difference (3 points).
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in daily practice, hence providing further confidence in
generalizability of our findings.
In conclusion, our results indicate that fatigue reported
by newly diagnosed patients with MDS is clinically
meaningful worse than that reported by the GP. Also,
compared with the IPSS classification, the IPSS-R provides
a better stratification of patients with regard to their fatigue
severity and, therefore, its use may further enhance more
personalized treatments.
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